Better Buy: Pfizer Inc. vs. Johnson & Johnson
With only one month remaining in 2017, it's pretty clear which big pharma stock has been the better pick this year between Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ). J&J's share price is up more than 20%, while Pfizer stock is only up a little over half as much.
Investing is kind of like driving, though. It's much more important to look ahead than it is to focus on what's in the rearview mirror. Which of these stocks is the better choice for investors in the years to come? Here's how Pfizer and Johnson & Johnson compare in three key categories.
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Aktie
26,36 €
-2,10 %
Deutliches Buy-Überwiegen bei Pfizer Inc. im Vergleich zu Sell-Einschätzungen.
Für Pfizer Inc. ergibt sich mit einem Kursziel von 41 € eine mögliche Steigerung von über 50% gegenüber 26.36 €.
